Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB)

Historical Holders from Q3 2021 to Q3 2025

Symbol
CTKB on Nasdaq
Type / Class
Equity / Common Stock - $0.001 par value
Shares outstanding
128M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
80M
Holdings value
$277M
% of all portfolios
0.001%
Grand Portfolio weight change
+0%
Number of holders
151
Number of buys
79
Number of sells
-77
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 13.1% -8.57% $56.2M -$6.63M 16.5M -10.6% BlackRock, Inc. 30 Jun 2025
VANGUARD GROUP INC 6.13% -17.3% $26.4M -$6.31M 7.77M -19.3% The Vanguard Group 30 Jun 2025
Topline Capital Management, LLC 5.3% $28.1M 6.78M Topline Capital Management, LLC 25 Sep 2025
BROWN CAPITAL MANAGEMENT LLC 3.9% -33.2% $17.2M -$8.7M 4.96M -33.6% Brown Capital Management, LLC 30 Sep 2025

Institutional Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 80M $277M +$1.87M $3.47 151
2025 Q2 79.4M $270M +$5.6M $3.40 156
2025 Q1 77.6M $311M -$4.13M $4.01 159
2024 Q4 77.3M $501M +$11.9M $6.49 150
2024 Q3 75M $415M -$14.5M $5.54 134
2024 Q2 76.2M $425M -$33.3M $5.58 126
2024 Q1 80.5M $540M +$11.1M $6.71 119
2023 Q4 78.9M $720M +$18M $9.12 101
2023 Q3 77.5M $428M -$3.53M $5.52 106
2023 Q2 77M $658M +$70M $8.54 100
2023 Q1 68.5M $630M +$39.1M $9.19 100
2022 Q4 64.2M $656M +$29.7M $10.21 100
2022 Q3 61.2M $900M +$129M $14.72 87
2022 Q2 52.9M $568M +$56.3M $10.73 81
2022 Q1 47.7M $515M +$122M $10.78 72
2021 Q4 35M $572M -$4.87M $16.32 51
2021 Q3 34.4M $744M +$744M $21.41 53